# IGF-1 LR3 vs HGH: Dosing, Use Cases, and Safety Monitoring
IGF-1 LR3 and HGH (somatropin) are frequently discussed together, but they are not interchangeable. HGH works upstream through growth hormone receptor signaling and downstream IGF-1 production. IGF-1 LR3 works more directly at the IGF-1 receptor with longer free exposure than native IGF-1.
If you are choosing between them, the decision is less about hype and more about objective goals, tolerance, monitoring discipline, and cycle structure.
Quick Comparison
Factor IGF-1 LR3 HGH (Somatropin) Primary pathway Direct IGF-1 receptor activity Growth hormone receptor, then IGF-1 axis Typical half-life ~20-30 hours ~2-3 hours plasma (longer biologic effects) Typical protocol style Shorter, targeted cycles Longer endocrine protocols Common use context Recomposition, recovery blocks Clinical GHD, body comp, recovery Regulatory status Research only (US) FDA-approved for specific indications
Mechanism Differences That Matter
HGH (Somatropin)
HGH increases circulating IGF-1 and affects:
Lipolysis and body composition Connective tissue remodeling Recovery and sleep architecture in some users Broader endocrine adaptation over time
Because HGH is upstream, effects can be more systemic and slower to stabilize.
IGF-1 LR3
IGF-1 LR3 is engineered for lower binding to IGF-binding proteins (IGFBPs), leading to:
Longer active window Direct anabolic and recovery signaling Higher sensitivity to dose escalation errors
Because it sits further downstream, protocol response can feel more acute but can also carry sharper glucose-management considerations.
Dosing Frameworks (Educational Reference)
IGF-1 LR3
Conservative: 20 mcg/day Standard: 40-80 mcg/day Advanced short block: 80-120 mcg/day Pattern: Often 4-8 week block, then washout
HGH (Somatropin)
Wellness/anti-aging context: 1-2 IU/day Body composition context: 2-4 IU/day Advanced short-term context: 4-6 IU/day Pattern: Often 3-6 month programs when medically supervised
These are not prescribing recommendations and should not replace clinician-directed dosing.
Reconstitution and Unit Clarity
One frequent source of errors is unit mismatch:
IGF-1 LR3 is commonly discussed in mcg HGH is commonly discussed in IU (or mg in clinical labeling)
Never copy a protocol without confirming unit conversion and vial concentration.
Safety and Monitoring Checklist
For either route, track objective data:
Fasting glucose and/or A1c IGF-1 labs Blood pressure Fluid retention/edema Joint discomfort or carpal tunnel-like symptoms Sleep quality and recovery markers
If stacking GH-axis compounds, increase lab frequency and lower starting doses.
Stacking Context
Common stacks discussed in advanced circles include:
HGH + IGF-1 LR3 HGH + CJC-1295/Ipamorelin IGF-1 LR3 + GH secretagogues
Stacking can increase both upside and risk. Most protocol failures come from aggressive starts, not lack of compounds.
Which One Fits Better?
Use-case framing:
Need broad endocrine support over months? HGH is usually the base discussion. Need a shorter targeted anabolic/recovery block? IGF-1 LR3 is often the candidate. Need medical legitimacy and approved-label pathways? HGH has the stronger clinical footing.
The best protocol is the one you can monitor, tolerate, and execute consistently.
FAQ
Q: Is IGF-1 LR3 stronger than HGH?
A: They are different tools. IGF-1 LR3 can feel more direct because it acts downstream at IGF-1 receptors, while HGH creates broader endocrine changes upstream.
Q: Can you run IGF-1 LR3 and HGH together?
A: Some advanced protocols do, but overlap increases complexity and risk. If combined, conservative dosing and frequent labs are essential.
Q: Why does HGH use IU and IGF-1 LR3 use mcg?
A: HGH is biologic-activity standardized in IU, while IGF-1 LR3 protocols are typically mass-based in micrograms.
Q: What is the biggest safety mistake?
A: Escalating too fast without glucose and IGF-1 monitoring.
---
PeptIQ helps you track compounds, cycle length, dose history, and response signals so decisions are based on data rather than guesswork.